chartexchange

IQVIA: 3 Key Takeaways for Long-Term Investors

The Motley Fool | Nov 9, 2026 8:32 PM EST

On its third-quarter 2026 earnings call, held on Oct. 27, 2026, IQVIA (NYSE:IQV) reported accelerating revenue growth and raised full-year financial guidance. The contract research organization (a provider that runs clinical trials and data analytics for pharmaceutical companies) is expanding profit margins while capturing record clinical bookings. Three things management said stand out. Contract research providers rely on multiyear booking trends to signal long-term revenue direction. Client demand accelerated as funding recovered among emerging biopharma companies, which are biotech firms without commercial products on the market. Software tools powered by artificial intelligence allow clients to analyze complex health data and shorten clinical trial timelines. Adoption of these automated tools strengthens customer retention and creates new subscription revenue. Continue reading

Read original article